by TractManager | Nov 21, 2023 | Evolving Evidence Review
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of systemic (chamber) hyperbaric oxygen therapy (HBOT) for the treatment of venous ulcers for improved wound closure...
by TractManager | Nov 16, 2023 | Evolving Evidence Review
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of the miraDry system (miraDry Inc.) in adult patients with primary axillary hyperhidrosis (PAH) for reduced sweat...
by TractManager | Nov 16, 2023 | Evolving Evidence Review
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of topical (local) hyperbaric oxygen therapy (HBOT) for the treatment of venous ulcers to improve wound...
by TractManager | Nov 16, 2023 | Evolving Evidence Review
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of percutaneous sacroplasty for the treatment of sacral insufficiency fractures (SIFs) in adults who primarily have...
by TractManager | Nov 15, 2023 | Emerging Technology Report
Rebonuputemcel Injectable Discogenic Cell Therapy (IDCT; DiscGenics Inc.) is an allogeneic progenitor cell therapy for the treatment of symptomatic early-to-moderate lumbar degenerative disc disease at a single level from L3 to S1.
Recent Comments